shot of 50mg/kg 17AAG one time per time on times 05, 712, and 1418, or by we.p. HNC cells through MDMX inhibition and elevated the antitumor activity of cisplatin synergistically, recommending a promising technique for dealing with HNC. Keywords:17AAG, p53, MDMX, neck and head cancer, apoptosis Mind and neck cancers (HNC) describes several tumors that occur in top of the aerodigestive tract like the dental or sinus cavity, pharynx, and larynx. HNC may be the 8th most common cancers worldwide, with an increase of than half of a million sufferers diagnosed each year.1Tobacco and alcohol consumption increases the risk of developing HNC, and oncogenic human papilloma virus is a rising cause of HNC with a high risk of oropharyngeal cancer.2,3Over 50% of HNCs display chromosomal loss at 17p, the site of theTP53gene, and harbor inactivatingTP53gene mutations.4,5The disruptive mutations ofTP53are associated with aggressive disease and poor survival.5High levels LDC000067 of two critical negative regulators of p53, mouse double minute 2 (MDM2) and mouse double minute X (MDMX) (also known as MDM4), are detected in more than 50% of HNCs.6 Impairment of wild-type p53 function occurs in human cancers and LDC000067 is caused by defective p53 regulation. MDM2, a RING domain E3 ubiquitin ligase, is the critical negative regulator of p53 and promotes its degradation.7MDMX, a homolog of MDM2, binds to the N-terminal region of p53 or heterodimerizes with MDM2, via C-terminal RING domain interaction, to augment p53 degradation.8,9Overexpression of MDM2 or MDM4 thus contributes to human cancer by disrupting the intricate interplay of MDM2 and p53.10 The concept of restoration of wild-type p53 function in tumors is greatly strengthened by mouse model studies.11,12Non-genotoxic low molecular mass compounds that interrupt the MDM2p53 interaction lead toin vivotumor regression.13,14Other small molecules and peptides, recently discovered, bind LDC000067 to MDMX and thereby interfere with the MDMXp53 interaction and activate p53 in MDMX-overexpressing cancer cells.15,16,17 Nutlin-3a is a small molecule that blocks MDM2-mediated p53 degradation, and LDC000067 thereby leads to cell death in cancer cells and tumor xenografts. 13It synergizes with conventional chemotherapeutic agents and is currently undergoing phase I and II clinical trials as combination therapy.18,19Inhibiting the interaction of Rabbit Polyclonal to CLIC3 p53 with MDM2 or MDMX using small molecules represents an attractive strategy for treating human cancers that bear wild-type p53 but overexpress MDM2 or MDM4;20,21,22however, this concept has rarely been tested in HNC.21,22A heat shock protein 90 (Hsp90) inhibitor, 17-(allylamino)-17-demethoxygeldanamycin (17AAG), was reported to interfere with the repressive p53MDMX complex and increase p53 transcriptional activity by inducing MDMX degradation.23This non-genotoxic small molecule selectively decreases the viability of solid cancer cells and increases the apoptotic activity of Nutlin-3a. The molecular mechanism underlying the antitumor activity of 17AAG in HNC cells remains unclear. Here, we show that inhibition of MDMX by 17AAG restores the tumor-suppressive function of wild-type p53 and increases the antitumor efficacy of Nutlin-3a and cisplatin in HNC. == Results == == 17AAG activates p53 in HNC cells by disrupting the p53MDMX interaction == In AMC-HN9 cells with wild-type p53 (wtp53), 17AAG significantly increased p53 levels, whereas dramatically decreasing the level of MDMX in a concentration-dependent manner, beginning 4 h after treatment (Figure 1a). p21 and cleaved poly(ADP-ribose) polymerase (PARP) also decreased along with elevation of p53 protein. 17AAG stabilized p53 protein by increasing its half-life andTP53mRNA level (Figure 1b), and quantitative reverse transcription-polymerase chain reaction (qRT-PCR) showed increased levels of mRNAs encoding the p53 targets MDM2, p21, PUMA, and BAX (Figure 1c). Notably, MDMX mRNA level remained unaffected by 17AAG, indicating that MDMX protein was downregulated mainly at the posttranscriptional level. The pan-caspase inhibitor Z-VAD did not block MDMX destabilization, indicating that MDMX degradation by LDC000067 17AAG was a primary cellular response rather than a secondary caspase-mediated degradation event (Figure 1d). In co-immunoprecipitation,.
